Prima BioMed Company Profile (NASDAQ:PBMD)

Analyst Ratings

Consensus Ratings for Prima BioMed (NASDAQ:PBMD) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $5.00 (446.39% upside)

Analysts' Ratings History for Prima BioMed (NASDAQ:PBMD)
Show:
DateFirmActionRatingPrice TargetActions
7/15/2016FBR & CoReiterated RatingOutperform$6.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/12/2016Maxim GroupReiterated RatingBuy$5.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/22/2016HC WainwrightReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/30/2015Roth CapitalInitiated CoverageBuy$6.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/28/2014 forward)

Earnings

Earnings History for Prima BioMed (NASDAQ:PBMD)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Prima BioMed (NASDAQ:PBMD)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Prima BioMed (NASDAQ:PBMD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Prima BioMed (NASDAQ:PBMD)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Prima BioMed (NASDAQ:PBMD)
DateHeadline
07/27/16 06:07 PMPrima BioMed Makes Progress For Breast Cancer Research
07/21/16 06:03 PMBrokers Issue Average Price Target Of 5.00 On Prima BioMed Ltd (PBMD) - Fiscal Standard
07/21/16 08:38 AMIs $6 Price Target Attainable For Prima BioMed Ltd (NASDAQ:PBMD)? - Investor Newswire
07/19/16 06:26 AMNew Broker Ratings For Prima BioMed Ltd (PBMD) - FTSE News
07/18/16 11:11 AMPrima Biomed Limited Ads (NASDAQ:PBMD) Sellers Covered 2.81% of Their Shorts - Consumer Eagle
07/14/16 09:20 AMHC Stocks Reports: Horizon Pharma PLC (NASDAQ:HZNP), Prima BioMed Ltd (ADR) (NASDAQ:PBMD) - share market updates (press release)
07/13/16 06:05 PMStrong Sell Calls For Prima BioMed Ltd (NASDAQ:PBMD) At 0 - Investor Newswire
07/12/16 02:43 AMPrima BioMed collaborates in Investigator Sponsored New Clinical Trial for IMP321 in Solid Tumors - [at noodls] - back ENGLISH SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) today announced a new collaborative study investigating the intra-tumoural injection of IMP321. The investigator sponsored study ...
07/11/16 10:25 AMHC Stocks Outlines: UnitedHealth Group Inc (NYSE:UNH), Prima BioMed Ltd (ADR) (NASDAQ:PBMD) - share market updates (press release)
07/07/16 08:36 AMPrima Biomed Limited Ads (NASDAQ:PBMD) Shorts Decreased by 2.81% After Short Covering - Engelwood Daily
07/06/16 05:55 PMPrima BioMed Ltd (NASDAQ:PBMD) Expected to Reach Highs Of $6 - Investor Newswire
07/02/16 05:22 PMPrima BioMed Ltd (PBMD) Current Analyst Ratings - Fiscal Standard
06/29/16 05:41 PMStrong Sell Calls Recommendations For Prima BioMed Ltd (NASDAQ:PBMD) At 0 - Investor Newswire
06/28/16 10:34 AMTop Wall Street Stories: Viavi Solutions Inc. (NASDAQ:VIAV), Prima Biomed Ltd. (NASDAQ:PBMD), Lifetime Brands ... - KC Register
06/28/16 10:34 AMPrima Biomed Limited Ads (NASDAQ:PBMD) Shorts Decreased by 2.81% After Short Covering - Press Telegraph
06/27/16 09:53 AMNext Weeks Broker Price Targets For Prima BioMed Ltd (PBMD) - Fiscal Standard
06/22/16 05:40 PMStrong Buy Calls Count For Prima BioMed Ltd (NASDAQ:PBMD) At 4 - Investor Newswire
06/22/16 05:40 PMPrima BioMed (PBMD) Says IMP321 Combo Safe, Well Tolerated at 5mg Level in Breast Cancer - StreetInsider.com
06/22/16 02:30 PMPrima Reports Favorable Initial Breast Cancer Study Data -
06/22/16 10:26 AMKeep An Eye On Nicox, OPK Gets FDA Nod, PBMD Abuzz, RDHL On The Move
06/22/16 10:26 AMPrima BioMed Announces First Safety, Pharmacokinetics and Immuno-Monitoring Data From Phase IIb Clinical Trial of IMP321
06/22/16 10:26 AMPrima BioMed (PBMD) Says IMP321 Combo Safe, Well Tolerated at 5mg Level in Breast Cancer
06/22/16 02:18 AM3:18 am Prima Biomed presents initial safety data from Phase IIb Clinical Trial of IMP321 -
06/21/16 10:07 AMPrima Biomed Ltd. (NASDAQ:PBMD) Went Up 2.94%: Navidea Biopharmaceuticals, Inc (NYSEMKT:NAVB), Rockwell ... - KC Register
06/15/16 05:43 PMTrend Of Rating Given To Prima BioMed Ltd (NASDAQ:PBMD) - Investor Newswire
06/07/16 08:29 AMPrima BioMed (PBMD) Regains Nasdaq Listing Compliance - StreetInsider.com
06/07/16 02:08 AMPrima BioMed to Maintain NASDAQ Listing - [at noodls] - back ENGLISH SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) the 'Company' has received notification from the Listing Qualifications Department of the NASDAQ Stock Market indicating that ...
06/02/16 08:43 AMPrima BioMed Ltd (PBMD) Do Brokers Advise Buy, Sell Or Hold? - Share Trading News - Prima BioMed Ltd (PBMD) Do Brokers Advise Buy, Sell Or Hold?Share Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Prima BioMed Ltd (PBMD). The latest reports which are currently in issue on Thursday 2nd of June state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 ...
05/16/16 10:44 AMSizzling Healthcare Stocks to Focus: Prima BioMed Ltd (NASDAQ:PBMD) , PAREXEL International Corporation ... - Is stories - Is storiesSizzling Healthcare Stocks to Focus: Prima BioMed Ltd (NASDAQ:PBMD) , PAREXEL International Corporation ...Is storiesPrima BioMed Ltd (NASDAQ:PBMD) decreased +0.00% to $1.00 while traded 935.39 thousand shares on 5/13/2016. The stock price negotiated for value between $0.96 to $1.06 in recent trading session. During the past 52 weeks, the stock's price witnessed ...
05/13/16 10:33 AMAdvantage: Australia. Biotechs Down Under Surge Ahead in Regenerative Medicine and Immuno-Oncology - An Australian company, Prima BioMed Ltd. (PBMD:NASDAQ; PRR:ASX), is doing a lot of work with LAG-3 (lymphocyte activation gene-3) checkpoint inhibitors. Another company looking to make use of the power of the checkpoint inhibitor is Viralytics Ltd. (VLA ...
05/13/16 10:33 AMPrima BioMed (PBMD), Sydys Enter Into Sale and Licensing Agreement - Get your Free Trial here. Prima BioMed Ltd (NASDAQ: PBMD) and U.S.-based Sydys Corporation, Inc. (OTC: SYYC) ("Sydys"), today announced an agreement through which Sydys will license Prima's CVac™ immuno-oncology program and oversee its future development.
05/12/16 10:28 AMHere's Why Prima BioMed Is Up 15% - Benzinga - CNA FinanceHere's Why Prima BioMed Is Up 15%BenzingaShares of Prima BioMed Ltd (ADR) PBMD, an Australia-based biotechnology company that is engaged in research, development and commercialization of licensed medical biotechnology, surged higher by more than 20 percent early Thursday morning.Prima BioMed, Sydys Enter Licensing Agreement to Develop CVac Immuno-oncology Program (NASDAQ:PBMD)Sonoran Weekly ReviewPrima BioMed Enters Into Sale and Licensing Agreement With Sydys to Advance CVac(TM) ProgramStockhouseall 6 news articles »
05/12/16 08:32 AMHere's Why Prima BioMed Is Up 15% - Shares of Prima BioMed Ltd (ADR) (NASDAQ: PBMD), an Australia-based biotechnology company that is engaged in research, development and commercialization of licensed medical biotechnology, surged higher by more than 20 percent early Thursday morning. Prima BioMed announced it has entered into an agreement with Sydys Corporation in which Sydys will license Prima's CVac immuno-oncology program (including manufacturing protocols, ...Full story available on Benzinga.com
05/12/16 05:13 AMPrima BioMed Enters Into Sale, Licensing Agreement With Sydys to Advance CVac Program - Prima BioMed Ltd (NASDAQ: PBMD) and U.S.-based Sydys Corporation, Inc. (OTC: SYYC) ("Sydys"), today announced an agreement through which Sydys will license Prima's CVac™ immuno-oncology program and oversee its future development. Sydys Corporation ( www.sydyscorp.com) is a publicly traded New York company that has been repurposed as a clinical stage biotechnology company in order to develop the CVac assets. Under the terms of the agreement, Sydys will license Prima's CVac related assets, including manufacturing protocols, clinical data from Phase I and Phase II trials, patents and know-how. Prima will also sell certain assets including some equipment and inventory to Sydys. Dr Sharron Gargosky, the former Chief Technical Officer of Prima who has overseen the development of CVac since 2010, will ...Full story available on Benzinga.com
05/12/16 03:25 AMPrima BioMed Enters Into Sale and Licensing Agreement With Sydys to Advance CVac(TM) Program - [Marketwired] - Prima BioMed Ltd
05/12/16 03:17 AMPrima BioMed enters into Sale and Licensing Agreement with SYDYS to advance CVac™ Program - [at noodls] - back ENGLISH Sydys Licenses Clinical‐Stage Immuno‐oncology Assets in 'spin out' transaction Potential for over A$400M in milestones and royalties Prima to receive 9.9% equity in Sydys SYDNEY, AUSTRALIA ...
05/09/16 10:46 AMHC Traders Alert: Athersys Inc. (ATHX), AbbVie Inc (ABBV), Prima BioMed Ltd (PBMD) - share market updates (press release) - share market updates (press release)HC Traders Alert: Athersys Inc. (ATHX), AbbVie Inc (ABBV), Prima BioMed Ltd (PBMD)share market updates (press release)Shares of Athersys, Inc. (NASDAQ:ATHX) ended Friday session in green amid volatile trading. The shares closed up +0.02 points or 0.90% at $2.24 with 1.29 million shares getting traded. Post opening the session at $2.35, the shares hit an intraday low ...Prima BioMed Ltd (PBMD) Broker Price Targets For The Coming WeekShare Trading Newsall 2 news articles »
05/03/16 11:06 AMThe $35,000 device that celebrities and the super-rich use at home to stream movies still in theaters -
05/03/16 10:18 AMPatent 5908210 - Shares of Prima BioMed Ltd (ADR) (NASDAQ: PBMD) were trading higher by more than 10 percent early Monday morning after the Australia-based biotechnology company announced it has received a patent from the Japanese Patent Office. Related Link: Allergan Gets ...
05/02/16 11:19 AMPrima BioMed (PBMD) Announces Japanese Patent for IMP321 in Cancer - StreetInsider.com - Web Breaking NewsPrima BioMed (PBMD) Announces Japanese Patent for IMP321 in CancerStreetInsider.comPrima BioMed Ltd (NASDAQ: PBMD) announces the granting of patent number 5908210 entitled "Use of Recombinant LAG-3 or the Derivatives thereof for Eliciting Monocyte Immune Response" by the Japanese Patent Office. This patent relates to Prima's ...This Weeks Broker Price Targets For Prima BioMed Ltd (PBMD)Share Trading NewsPrimaBioMed Jumps 10% As Company Receives Japanese Patent GrantBenzingaPrima BioMed Ltd (PBMD) Short Interest Down 19.7% in AprilWeb Breaking Newsall 4 news articles »
05/02/16 08:55 AMPrimaBioMed Jumps 10% As Company Receives Japanese Patent Grant - Shares of Prima BioMed Ltd (ADR) (NASDAQ: PBMD) were trading higher by more than 10 percent early Monday morning after the Australia-based biotechnology company announced it has received a patent from the Japanese Patent Office. Related Link: Allergan Gets Positive Opinion From EU's CHMP ...Full story available on Benzinga.com
05/02/16 02:30 AMJapanese Patent grants for IMP321 in Cancer - [Other] - Japanese Patent grants for IMP321 in Cancer
04/27/16 10:56 AMNew Analyst Ratings On Prima BioMed Ltd (PBMD) - Risers & Fallers - New Analyst Ratings On Prima BioMed Ltd (PBMD)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Prima BioMed Ltd (PBMD). The latest broker reports which are currently outstanding on Wednesday 27th of April state 0 analysts have a rating of “strong buy”, 0 analysts ...
04/26/16 10:57 AMNext Weeks Broker Price Targets For Prima BioMed Ltd (PBMD) - Share Trading News - Next Weeks Broker Price Targets For Prima BioMed Ltd (PBMD)Share Trading NewsPrima BioMed Ltd has a 50 day moving average of 0.95 and a 200 day moving average of 1.04. The stock's market capitalization is 71.17M, it has a 52-week low of 0.42 and a 52-week high of 6.48. The share price of the company (PBMD) was down -2.68%, ...and more »
04/25/16 10:48 AMAnalyst Review: Prima BioMed Ltd (PBMD) - Risers & Fallers - Analyst Review: Prima BioMed Ltd (PBMD)Risers & FallersA number of investment brokers have recently updated their price targets on shares of Prima BioMed Ltd (PBMD). According to the latest broker reports outstanding on Monday 25th of April, 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 ...and more »
04/22/16 11:03 AM3 Trending Stocks: Prima Biomed Ltd. (PBMD), Gold Fields Ltd. (GFI), UGI Corporation (UGI) - iStreetWire - 3 Trending Stocks: Prima Biomed Ltd. (PBMD), Gold Fields Ltd. (GFI), UGI Corporation (UGI)iStreetWirePrima Biomed Ltd. (PBMD) continued its downward trend with the stock declining -2.61% or $-0.03 to close the day at $1.12 on light trading volume of 1.46M shares, compared to its three month average trading volume of 260.79K. The Sydney New South ...
04/19/16 04:47 AMCoverage initiated on Prima Biomed by Maxim Group -
01/27/16 05:00 PMUS Patent Grants for IMP731 Antibody - [Marketwired] - Prima BioMed Ltd announces the granting of patent number US 9,244,059 entitled "Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and ...
01/26/16 04:50 PMPrima BioMed Initiates Phase I Melanoma Study in Australia - [Other] - Prima BioMed Ltd , a leading immuno-oncology company, is pleased to announce the initiation of the first clinical trial site for TACTI-mel, a Phase I clinical study in melanoma using its lead compound ...
12/31/15 01:21 PMWhy Are These Four Stocks in Green on Thursday? - [at Insider Monkey] - The markets are slightly down today with all three indices in the red, but shares of Prima BioMed Ltd (ADR) (NASDAQ:PBMD), Twitter Inc (NYSE:TWTR), WPX Energy Inc (NYSE:WPX), and Southwestern Energy Company (NYSE:SWN) are going the opposite way. So let’s take a closer look at these stocks and see what the smart money investors think about […]

Social

About Prima BioMed

Prima BioMed logoPrima BioMed Limited is an Australia-based biotechnology company. The Company is engaged in research, development and commercialization of licensed medical biotechnology. The Company focuses on cancer immunotherapy research. The Company's main pipeline of products is based on the LAG-3 immune control mechanism, which plays a role in the regulation of the T cell immune response. The Company's product is a T cell immunostimulatory factor (APC activator), IMP321, for cancer chemoimmunotherapy, which has completed Phase II trials. In addition, it has developed infrastructure for a cell-based therapy manufacturing platform and taken CVac, an autologous dendritic cell-based product through Phase II clinical trials for ovarian cancer patients in remission. The Company's other products include IMP731 for autoimmune disease, and IMP701 for cancer and chronic infectious disease.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: PBMD
  • CUSIP:
Key Metrics:
  • Previous Close: $0.92
  • 50 Day Moving Average: $0.9706
  • 200 Day Moving Average: $0.9604
  • P/E Ratio: N/A
  • P/E Growth: 0.0000
  • Market Cap: $62.78M
  • Beta: 1.95
  • Current Year EPS Consensus Estimate: $-0.5 EPS
  • Next Year EPS Consensus Estimate: $-0.09 EPS
Additional Links:
Prima BioMed (NASDAQ:PBMD) Chart for Thursday, July, 28, 2016